# A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients

> **NCT00360334** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 235 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** exenatide
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT00360334
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2015-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00360334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00360334, "A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00360334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*